Compensation for changes in dose-rate in radical low-dose-rate brachytherapy: a radiobiological analysis of a randomised clinical trial.
Affiliation
Biostatistics Group, School of Epidemiology and Health Sciences, University of Manchester, Manchester M13 9PT, UK.Issue Date
2004-01
Metadata
Show full item recordAbstract
BACKGROUND AND PURPOSE: This study reanalysed the results of the Cs-137 low-dose-rate brachytherapy trials for stage I and II cervix carcinoma at the Christie Hospital, Manchester, UK, in order to quantify the clinical outcome as a function of dose, and to extract radiobiological parameter values by modelling the data for local control and morbidity. PATIENTS AND METHODS: Kaplan-Meier survival curves and Cox regression analyses were used to analyse the time to event data. Linear-quadratic (LQ) analysis was also used in a mixture model, incorporating a half-time for repair, a time factor, and a heterogeneity function between patients. Full 5-year follow-up data were available for 339 patients receiving Cs-137 doses between 60 and 75 Gy delivered at 1.4-1.8 Gy/h, and 178 patients receiving a Ra-226 dose of 75 Gy at 0.5 Gy/h, using two insertions 7-10 days apart. RESULTS: With the increased dose-rate, a dose reduction between 20 and 25% was required to achieve a similar morbidity rate. This reduction had a detrimental effect on tumour control, by about 15% points. Unexpectedly, this loss in local control did not lead to a decrease in cancer-specific survival. For both tumour control and complications a high alpha/beta and short half-time for repair best fitted the data, suggesting that consequential late reactions may be responsible for much of the bowel and urinary morbidity after these short treatments. The variability in response between patients was greater (CV 40%) for morbidity than for tumour control (CV 17%), probably reflecting the greater variation in dose at the target tissue. There was no significant dependence on overall treatment time detected over the 7-10-day range of these treatments. CONCLUSIONS: The therapeutic ratio was somewhat less for the higher dose-rate, in agreement with radiobiological expectations, although cancer-specific survival was inexplicably unchanged. The LQ-parameter analysis suggests that high alpha/beta ratios and/or short repair half-times are applicable for both tumour and normal tissue responses in these treatments.Citation
Compensation for changes in dose-rate in radical low-dose-rate brachytherapy: a radiobiological analysis of a randomised clinical trial. 2004, 70 (1):63-74 Radiother OncolJournal
Radiotherapy and OncologyDOI
10.1016/j.radonc.2003.11.010PubMed ID
15036854Type
ArticleLanguage
enISSN
0167-8140ae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2003.11.010
Scopus Count
Related articles
- Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix.
- Authors: Leborgne F, Fowler JF, Leborgne JH, Zubizarreta E, Chappell R
- Issue date: 1997
- Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series.
- Authors: Ferrigno R, Nishimoto IN, Novaes PE, Pellizzon AC, Maia MA, Fogarolli RC, Salvajoli JV
- Issue date: 2005 Jul 15
- Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer.
- Authors: Wang CJ, Huang EY, Sun LM, Chen HC, Fang FM, Hsu HC, Changchien CC, Leung SW
- Issue date: 2004 May 1
- Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone.
- Authors: Gasinska A, Fowler JF, Lind BK, Urbanski K
- Issue date: 2004
- Prospective study of HDR (192Ir) versus MDR (137Cs) intracavitary brachytherapy for carcinoma of the uterine cervix.
- Authors: Tanaka E, Oh RJ, Yamada Y, Shiomi H, Nakamura S, Shimamoto S, Teshima T, Inoue T, Inoue T
- Issue date: 2003